The discoverer of free PSA and his colleagues assess the clinical utility of this most widely used disease biomarker. The article encompasses recently published data from randomized screening trials, and the potential of PSA density, dynamics and subforms to enhance the predictive capacity of total PSA. The PSA characteristics of BPH, prostatitis and prostate cancer are summarized, and the effects of age and obesity presented.
- David Ulmert
- M. Frank O'Brien
- Hans Lilja
